Nektar Therapeutics (NKTR)
Develops investigational immune-modulating medicines for autoimmune disease and cancer.
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 124.83% | 35.81M shares | |
|---|---|---|---|
| 258 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.30% | 85.8K shares | |
| 3 holders · as of Aug 20, 2026 | |||
| Adds to | 125.13% | ||
28.69M company shares as of Sep 12, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (34.14M in the company's Sep 22, 2026 report, 28.69M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 125.13%; nothing is left for Other.
13F, as of Jun 30, 2026
258 holders · 35.81M shares · 79 new positions · 178 increased · 44 reduced · 43 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 5.07M | 17.67% | +764.7K | Aug 13, 2026 |
| Two Seas Capital LP | 3.09M | 10.78% | +1.13M | Aug 12, 2026 |
| BlackRock, Inc. | 2.94M | 10.25% | +2.25M | Aug 7, 2026 |
| BVF Inc/IL | 2.39M | 8.33% | −168.5K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.50M | 5.22% | +299.8K | Aug 13, 2026 |
| Two Sigma Investments, LP | 1.20M | 4.19% | +271.3K | Aug 14, 2026 |
| Vestal Point Capital, LP | 1.00M | 3.49% | +715.0K | Aug 14, 2026 |
| Morgan Stanley | 936.6K | 3.26% | +277.2K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 4.30M | 13G | May 6, 2026 |
| BlackRock, Inc. | 7.80% | 2.64M | 13G | Jul 29, 2026 |
| Two Seas Capital LP | 6.80% | 1.96M | 13G | Apr 17, 2026 |
| Susquehanna Portfolio Strategies, LLC | 6.30% | 1.24M | 13G | Nov 13, 2025 |
| Biotechnology Value Fund L P | 5.30% | 1.52M | 13G | May 15, 2026 |
| Vanguard Capital Management | 5.17% | 1.75M | 13G | Jul 31, 2026 |
| Robin C. Johnincl. Finny Kuruvilla, M.D. Ph. D., Eventide Asset Management, LLC | 5.11% | 13G | Nov 14, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Jonathan Zalevskyofficer: Chief R&D Officer | Sale | 186 | $71.98 | 9,570 |
| Aug 18, 2026 | Howard W. Robindirector, officer: President & CEO | Sale | 418 | $71.98 | 54,627 |
| Jun 30, 2026 | Jonathan Zalevskyofficer: Chief R&D Officer | Sale | 5,681 | $70.00 | 9,756 |
| Jun 17, 2026 | Howard W. Robindirector, officer: President & CEO | Sale · 2 lots | 10,000 | $61.19 | 55,045 |
| Jun 16, 2026 | Howard W. Robindirector, officer: President & CEO | Sale · 2 lots | 10,000 | $60.32 | 65,045 |
| Jun 15, 2026 | Jonathan Zalevskyofficer: Chief R&D Officer | Sale | 5,538 | $60.71 | 15,437 |
| May 19, 2026 | Howard W. Robindirector, officer: President & CEO | Sale | 444 | $65.51 | 75,045 |
| May 19, 2026 | Jonathan Zalevskyofficer: Chief R&D Officer | Sale | 199 | $65.51 | 20,975 |
| Feb 18, 2026 | Howard W. Robindirector, officer: President & CEO | Sale | 423 | $73.00 | 75,489 |
| Feb 18, 2026 | Jonathan Zalevskyofficer: Chief R&D Officer | Sale | 180 | $73.00 | 21,174 |
House and Senate disclosures
Not reported.